Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity

INTRODUCTION: The effect of certolizumab pegol (CZP) on patient-reported outcomes (PROs) was investigated in 1063 patients with rheumatoid arthritis (RA) from the REALISTIC trial (double-blind, placebo-controlled to week 12, open-label to week 28; randomized 4:1 [CZP:placebo]). Correlations between...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Arthritis Res Ther
Главные авторы: Pope, Janet, Bingham, Clifton O., Fleischmann, Roy M., Dougados, Maxime, Massarotti, Elena M., Wollenhaupt, Jürgen, Duncan, Benjamin, Coteur, Geoffroy, Weinblatt, Michael E.
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2015
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4662806/
https://ncbi.nlm.nih.gov/pubmed/26614481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-015-0849-1
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы